Goldman Sachs
SPRO icon

Goldman Sachs’s Spero Therapeutics SPRO Stock Holding History

Goldman Sachs’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$568K Buy
+256,985
New +$672K ﹤0.01% 5620
2022
Q4 		– Sell
-55,438
Closed -$111K – 6249
2022
Q3 		$111K Sell
55,438
-247,763
-82% -$246K ﹤0.01% 5663
2022
Q2 		$225K Buy
303,201
+161,775
+114% +$470K ﹤0.01% 5588
2022
Q1 		$1.23M Buy
141,426
+2,815
+2% +$28.8K ﹤0.01% 4657
2021
Q4 		$2.22M Buy
138,611
+1,032
+0.8% +$16.4K ﹤0.01% 4171
2021
Q3 		$2.53M Buy
137,579
+1,317
+1% +$21.1K ﹤0.01% 3969
2021
Q2 		$1.9M Sell
136,262
-119,538
-47% -$1.67M ﹤0.01% 4254
2021
Q1 		$3.77M Buy
255,800
+214,179
+515% +$3.77M ﹤0.01% 3407
2020
Q4 		$807K Buy
41,621
+10,256
+33% +$160K ﹤0.01% 4337
2020
Q3 		$350K Sell
31,365
-20,593
-40% -$244K ﹤0.01% 4657
2020
Q2 		$703K Buy
51,958
+24,696
+91% +$277K ﹤0.01% 4188
2020
Q1 		$220K Sell
27,262
-4,284
-14% -$37.8K ﹤0.01% 4661
2019
Q4 		$303K Buy
31,546
+17,740
+128% +$191K ﹤0.01% 4742
2019
Q3 		$146K Sell
13,806
-8,171
-37% -$86.1K ﹤0.01% 4909
2019
Q2 		$253K Buy
21,977
+9,285
+73% +$112K ﹤0.01% 4687
2019
Q1 		$163K Sell
12,692
-3,505
-22% -$37.2K ﹤0.01% 4846
2018
Q4 		$100K Buy
+16,197
New +$131K ﹤0.01% 4997

Other funds holding SPRO

GP
GSK plc London $602M AUM
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Goldman Sachs's SPRO Position: Q2 2026 in Review

Goldman Sachs opened a new position in Spero Therapeutics (SPRO) in Q2 2026: 256,985 shares worth $568K. The stake represents ﹤0.01% of the portfolio and ranks #5620 among its holdings. This is a return to the name: Goldman Sachs previously reported a position in SPRO as recently as Q3 2022.

Goldman Sachs first reported a position in SPRO in Q4 2018 and has held it in 17 quarters since. The position peaked at $3.77M in Q1 2021. 60 funds tracked by Wall St. Rank hold SPRO as of Q2 2026.

  • Goldman Sachs held 256,985 shares of Spero Therapeutics worth $568K as of Q2 2026.
  • Spero Therapeutics was a new Goldman Sachs position in Q2 2026.
  • Spero Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #5620 holding.
  • Goldman Sachs first reported a position in Spero Therapeutics in Q4 2018 and has held it in 17 quarters since.
  • Goldman Sachs's Spero Therapeutics position peaked at $3.77M in Q1 2021.
  • 60 funds tracked by Wall St. Rank held Spero Therapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.